PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 186 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 1.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $18,285,000 | +56.2% | 239,583 | +23.2% | 0.01% | +66.7% |
| Q4 2021 | $11,704,000 | +5.8% | 194,516 | -1.6% | 0.01% | 0.0% |
| Q3 2021 | $11,067,000 | +6.5% | 197,618 | +15.4% | 0.01% | 0.0% |
| Q2 2021 | $10,388,000 | -21.0% | 171,189 | -8.7% | 0.01% | -25.0% |
| Q1 2021 | $13,147,000 | +36.8% | 187,572 | +16.8% | 0.01% | +33.3% |
| Q4 2020 | $9,613,000 | -14.2% | 160,648 | -13.8% | 0.01% | -25.0% |
| Q3 2020 | $11,201,000 | +23.5% | 186,315 | +7.8% | 0.01% | +14.3% |
| Q2 2020 | $9,068,000 | +87.0% | 172,816 | +19.5% | 0.01% | +75.0% |
| Q1 2020 | $4,849,000 | -27.9% | 144,631 | -2.6% | 0.00% | -20.0% |
| Q4 2019 | $6,725,000 | +71.2% | 148,459 | +43.9% | 0.01% | +66.7% |
| Q3 2019 | $3,928,000 | -15.3% | 103,169 | -3.2% | 0.00% | -25.0% |
| Q2 2019 | $4,637,000 | +39.9% | 106,630 | +22.5% | 0.00% | +33.3% |
| Q1 2019 | $3,314,000 | -29.9% | 87,063 | -20.8% | 0.00% | -40.0% |
| Q4 2018 | $4,727,000 | -12.9% | 109,889 | -0.5% | 0.01% | 0.0% |
| Q3 2018 | $5,430,000 | +101.9% | 110,478 | +31.7% | 0.01% | +66.7% |
| Q2 2018 | $2,689,000 | +18.5% | 83,906 | +15.2% | 0.00% | +50.0% |
| Q1 2018 | $2,270,000 | -36.9% | 72,862 | -7.5% | 0.00% | -50.0% |
| Q4 2017 | $3,595,000 | -0.8% | 78,755 | -18.4% | 0.00% | 0.0% |
| Q3 2017 | $3,624,000 | -31.0% | 96,504 | -12.4% | 0.00% | -33.3% |
| Q2 2017 | $5,253,000 | +30.5% | 110,124 | +24.8% | 0.01% | 0.0% |
| Q1 2017 | $4,024,000 | +121.6% | 88,244 | +56.9% | 0.01% | +100.0% |
| Q4 2016 | $1,816,000 | +14.4% | 56,235 | +21.3% | 0.00% | +50.0% |
| Q3 2016 | $1,587,000 | +165.4% | 46,371 | +161.6% | 0.00% | +100.0% |
| Q2 2016 | $598,000 | -48.7% | 17,723 | -19.5% | 0.00% | -50.0% |
| Q1 2016 | $1,166,000 | -29.5% | 22,012 | +2.1% | 0.00% | -33.3% |
| Q4 2015 | $1,655,000 | +143.4% | 21,551 | +30.2% | 0.00% | +200.0% |
| Q3 2015 | $680,000 | -42.8% | 16,556 | -1.4% | 0.00% | -50.0% |
| Q2 2015 | $1,188,000 | -40.9% | 16,797 | -25.7% | 0.00% | -50.0% |
| Q1 2015 | $2,009,000 | +17.8% | 22,606 | +17.5% | 0.00% | 0.0% |
| Q4 2014 | $1,706,000 | -14.1% | 19,243 | -6.2% | 0.00% | 0.0% |
| Q3 2014 | $1,987,000 | +422.9% | 20,505 | +395.3% | 0.00% | +300.0% |
| Q2 2014 | $380,000 | – | 4,140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |